GlassScriptPhysician profile
Rabih S Halabi
NPI 1598972861
$604,069.02
in general payments reported to CMS, 2019-2025
34 companies · $236K in 2025
The $236K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,888 · 2020: $198 · 2021: $18K · 2022: $20K · 2023: $53K · 2024: $274K · 2025: $236K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $471K · Travel and Lodging: $55K · Consulting Fee: $22K · Food and Beverage: $15K · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $471,001.90 |
| Travel and Lodging | $55,155.06 |
| Consulting Fee | $21,893.00 |
| Food and Beverage | $14,977.62 |
| Education | $244.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $340,168.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $242,298.97 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $6,690.00 | 2019-2025 | Xolair, Tecentriq |
| Regeneron Pharmaceuticals, INC. | $3,672.00 | 2024 | Dupixent |
| Emd Serono, INC. | $3,570.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $2,754.75 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Insmed, INC. | $1,520.15 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $1,213.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $283.96 | 2021-2025 | |
| Baxter Healthcare | $237.67 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.24 | 2019-2022 | |
| Pulmonx Corporation | $187.43 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $177.84 | 2025 | Ohtuvayre |
| Amgen INC. | $165.68 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $143.65 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $93.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.28 | 2022-2023 | Glassia |
| Novartis Pharmaceuticals Corporation | $76.39 | 2019-2024 | |
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Grifols USA, LLC | $51.31 | 2022-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $48.58 | 2022-2023 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $43.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.53 | 2022 | |
| Philips North America LLC | $31.87 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $29.31 | 2023 | Acthar |
| Merck Sharp & Dohme LLC | $29.07 | 2019-2020 | |
| Shionogi INC | $26.94 | 2023 | Fetroja |
| Pfizer INC. | $26.92 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $24.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.33 | 2022 | |
| Medical Graphics Corporation | $19.17 | 2021 | |
| Electromed, INC. | $16.43 | 2024 | Smartvest |
| Gilead Sciences, INC. | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabih Halabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.